In vitro and in vivo antitumor effect of a trivalent bispecific antibody targeting ErbB2 and CD16

Cancer Biology and Therapy

Volumn 7, Issue 11, 2008, Pages 1744-1750

  Lu, Han ^a,b   Shi, Ming ^a   Wang, Mingli ^a,b   Xie, Zhigang ^c   Hu, Meiru ^a   Yu, Ming ^a   Shen, Beifen ^a   Ma, Yuanfang ^b   Guo, Ning ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b HENAN UNIVERSITY   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Bispecific antibody; CD16; ErbB2; Immunotherapy; Tumor

Indexed keywords

BISPECIFIC ANTIBODY; CD16 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; ERBB2 PROTEIN, HUMAN; FC RECEPTOR; IMMUNOGLOBULIN G; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING KINETICS; CELL KILLING; CELL STRAIN MCF 7; CELL SURFACE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG TARGETING; EFFECTOR CELL; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DOMAIN; RECEPTOR DENSITY; TUMOR CELL; XENOGRAFT; ANIMAL; BINDING SITE; BIOSYNTHESIS; CELL SEPARATION; CHEMISTRY; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; FLOW CYTOMETRY; IMMUNOTHERAPY; METABOLISM; PROCEDURES; TIME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; BINDING SITES; CELL LINE, TUMOR; CELL SEPARATION; CERCOPITHECUS AETHIOPS; COS CELLS; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; IN VITRO TECHNIQUES; PROTEIN BINDING; RECEPTOR, ERBB-2; RECEPTORS, IGG; TIME FACTORS;

EID: 56449124449     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.11.6725     Document Type: Article

References (38)

1. Steplewski Z, Lubeck MD, Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 1983; 221:865-7.
2. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1:118-29.
3. van Spriel AB, van Ojik HH, van De Winkel JG. Immunotherapeutic perspective for bispecific antibodies. Immunol Today 2000; 21:391-7.
4. van de Winkel JG, Bast B, de Gast GC. Immunotherapeutic potential of bispecific antibodies. Immunol Today 1997; 18:562-4.
5. Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 2006; 12:4036-42.
6. Asano R, Watanabe Y, Kawaguchi H, Fukazawa H, Nakanishi T, Umetsu M, Hayashi H, K0atayose Y, Unno M, Kudo T, Kumagai I. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J Biol Chem 2007; 282:27659-65.
7. Tita-Nwa F, Moldenhauer G, Herbst M, Kleist C, Ho AD, Kornacker M. Cytokineinduced killer cells targeted by the novel bispecific antibody CD19 x CD5 (HD37 x T5.16) efficiently lyse B-lymphoma cells. Cancer Immunol Immunother 2007; 56:1911-20.
8. Jung G, Ledbetter JA, Müller-Eberhard HJ. Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc Natl Acad Sci USA 1987; 84:4611-5.
9. Jung G, Freimann U, Von Marschall Z, Reisfeld RA, Wilmanns W. Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur J Immunol 1991;21:2431-5.
10. Kroesen BJ, Bakker A, van Lier RA, The HT, de Leij L. Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28. Cancer Res 1995; 55:4409-15.
11. Müller D, Kontermann RE. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 2007; 9:319-26.
12. Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, Wolf J, Kapp U, Diehl V, Pfreundschuh M. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 1993; 55:830-6.
13. Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 1993; 53:94-100.
14. Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy. J Immunol 1994; 152:2385-92.
15. Fury MG, Lipton A, Smith KM, Winston CB, Pfister DG. A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother 2008; 57:155-63.
16. Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, Kiener PA. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer Res 2007; 67:3927-35.
17. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passiveand active immunity to melanoma. Proc Natl Acad Sci USA 1998; 95:652-6.
18. Xie Z, Shi M, Feng J, Yu M, Sun Y, Shen B, Guo N. A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells. Biochem Biophys Res Commun 2003; 311:307-12.
19. Xie Z, Guo N, Yu M, Hu M, Shen B. A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. J Immunol Methods 2005; 296:95-101.
20. Feng J, Xie Z, Yu M, Guo N, Shen B. The difference of binding epitopes on human CD16 (FcgammaRIII) interacted with hIgG1 and monoclonal antibody B88-9. Mol Immunol 2004; 41:93-8.
21. McCammon JR. Radioimmunofluorescent antibody technique for detection of reovirus antigen in cell culture. Infect Immun 1976; 14:811-5.
22. Imir T, Gibbs DL, Sibbitt WL Jr, Bankhurst AD. Generation of natural killer cells and lymphokine-activated killer cells in human AB serum or fetal bovine serum. Clin Immunol Immunopathol 1985; 36:289-96.
23. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6:443-6.
24. Segal DM, Weiner GJ, Weiner LM. Bispecific antibodies in cancer therapy. Curr Opin Immunol 1999; 11:558-62.
25. Talac R, Nelson H. Current perspectives of bispecific antibody-based immunotherapy. J Biol Regul Homeost Agents 2000; 14:175-81.
26. van Ojik HH, Valerius T. Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy. Crit Rev Oncol Hematol 2001; 38:47-61.
27. van Spriel AB, van Ojik HH, van De Winkel JG. Immunotherapeutic perspective for bispecific antibodies. Immunol Today 2000; 21:391-7.
28. Withoff S, Helfrich W, de Leij LF, Molema G. Bi-specific antibody therapy for the treatment of cancer. Curr Opin Mol Ther 2001; 3:53-62.
29. Wang H, Liu Y, Wei L, Guo Y. Bi-specific antibodies in cancer therapy. Adv Exp Med Biol 2000; 465:369-80.
30. Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW. Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function. J Immunol 1989; 43:1650-5.
31. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 1995; 13:2281-92.
32. Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother 1995; 4:453-6.
33. Weiner LM, Alpaugh RK, Amoroso AR, Adams GP, Ring DB, Barth MW. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII. Cancer Immunol Immunother 1996; 42:141-50.
34. Hsieh-Ma ST, Eaton AM, Shi T, Ring DB. In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III. Cancer Res 1992; 52:6832-9.
35. Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM, et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1995; 1:73-81.
36. Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM, Marks JD. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinitydriven selection. J Mol Biol 1996; 255:28-43.
37. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 1996; 263:551-67.
38. Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 2004; 279:53907-14.